Renalytix plc (RNLXY)
2024-09-30 | ||||
|---|---|---|---|---|
| Revenue | 522 | |||
| Costs incurred related to the performance of the services | 422 | |||
| Gross profit (loss) | 100 | |||
| Research and development expenses | 921 | |||
| General and administrative | 3,271 | |||
| Total operating expenses | 4,192 | |||
| Loss from operations | -4,093 | |||
| Gain (loss), foreign currency transaction, before tax | 37 | |||
| Fair value adjustment to vericidx investment | -97 | |||
| Fair value adjustment to convertible debt | 762 | |||
| Other (expense) income, net | -5 | |||
| Income (loss) from continuing operations before income taxes, noncontrolling interest | -4,726 | |||
| Income tax expense (benefit), total | 2 | |||
| Net loss | -4,728 | |||
| Changes in fair value of convertible notes | -125 | |||
| Foreign exchange translation adjustment | -461 | |||
| Comprehensive loss | 5,314 | |||
| Basic eps | -0.04 | |||
| Diluted eps | -0.04 | |||
| Basic average shares | 105,697,401 | |||
| Diluted average shares | 105,697,401 | |||